Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials

Rambout, Lisa; Hopkins, Laura; Hutton, Brian; Fergusson, Dean
August 2007
CMAJ: Canadian Medical Association Journal;8/28/2007, Vol. 177 Issue 5, p469
Academic Journal
Background: Human papillomavirus (HPV) is now known to be a necessary cause of cervical cancer, and prophylactic HPV vaccines aimed at preventing genital warts, precancerous cervical lesions and cervical cancer are now available. To gauge the potential impact on disease burden, we performed a systematic review of the evidence from randomized controlled trials. Methods: We conducted a systematic search of the literature to identify all randomized controlled trials of prophylactic HPV vaccination. Reports in 5 electronic databases covering 1950 to June 2007 (MEDLINE, MEDLINE in process, EMBASE, the Cochrane Central Registry of Controlled Trials and the Cochrane Library), bibliographies of all included studies and of narrative reviews (2006-2007), clinical trial registries, Google Scholar, public health announcements, selected conference proceedings (2004-2007) and manufacturers' information on unpublished data or ongoing trials were screened against predefined eligibility criteria by 2 independent reviewers. Vaccines had to contain coverage against at least 1 oncogenic HPV strain. The primary outcome of interest was the frequency of high-grade cervical lesions (high-grade squamous intraepithelial lesion, or grade 2 or 3 cervical intraepithelial neoplasia). The secondary outcomes were persistent HPV infection, low-grade cervical lesions (low-grade squamous intraepithelial lesion or grade 1 cervical intraepithelial neoplasia), external genital lesions, adverse events and death. Meta-analysis of the data was done in all cases where adequate clinical and methodological homogeneity existed. Results: Of 456 screened reports, 9 were included in the review (6 were reports of randomized controlled trials and 3 were follow-up reports of initial trials). Findings from the meta-analysis showed that prophylactic HPV vaccination was associated with a reduction in the frequency of high-grade cervical lesions caused by vaccine-type HPV strains compared with control groups: Peto odds ratio 0.14 (95% confidence interval [CI] 0.09-0.21) from combined per-protocol analyses, and 0.52 (95% CI 0.43-0.63) from modified intention- to-treat analyses. Vaccination was also highly efficacious in preventing other HPV-related infection and disease outcomes, including persistent HPV infection, low-grade lesions and genital warts. The majority of adverse events were minor. The incidence of serious adverse events and death were balanced between the vaccine and control groups. Interpretation: Among women aged 15-25 years not previously infected with vaccine-type HPV strains, prophylactic HPV vaccination appears to be highly efficacious in preventing HPV infection and precancerous cervical disease. Longterm follow-up is needed to substantiate reductions in cervical cancer incidence and mortality.


Related Articles

  • Success for Cervical Cancer Vaccine. Grose, Simon // Australasian Science;Aug2007, Vol. 28 Issue 7, p39 

    The article discusses the findings of clinical trials of Gardasil vaccine from Merck to protect young women against infection by four strains of human papillomavirus (HPV) linked to cervical cancer. A study found that there are possible linkages between cancers of the upper throat and HPV...

  • Changeover to added protection cervical cancer jab.  // Community Practitioner;Jan2012, Vol. 85 Issue 1, p8 

    The article focuses on the effectiveness of Gardasil in treating cervical cancer, sexually transmitted disease, and genital warts.

  • Clinical Indications for Human Papillomavirus Vaccination. Herzog, Thomas J.; Vallerie, Amy; Smith, Jennifer S.; Wright, Jason D. // Clinical Ovarian Cancer;Jun2008, Vol. 1 Issue 1, p36 

    With the approval of a vaccine to prevent human papillomavirus (HPV) infection and the pending approval of a second vaccine, an exciting era has dawned that provides clinicians the opportunity to prevent a majority of lower genital tract cancers. Herein, we describe the quadrivalent and bivalent...

  • Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males. Garnock-Jones, Karly; Giuliano, Anna // Drugs in R&D;2012, Vol. 12 Issue 4, p235 

    The article presents a discussion of the efficacy of human papillomavirus (HPV) vaccine for the prevention of genital warts caused by HPV types 6, 11, 16, and 18 in male, adapted from an article published in the 2011 issue of the journal "Drugs in R&D."

  • HPV vaccine given to males prevents genital warts.  // Contemporary Pediatrics;Mar2011, Vol. 28 Issue 3, p10 

    No abstract available.

  • Expansion of cervical cancer protection through HPV vaccine in BC. Naus, Monika // British Columbia Medical Journal;Sep2012, Vol. 54 Issue 7, p346 

    The article deals with the recommendation of the National Advisory Committee on Immunization to use the human papillomavirus (HPV) vaccine to prevent genital warts aside from using the vaccine for cervical cancer protection. A list of the providers that will deliver the expanded program is...

  • What to Do About HPV? Kotz, Deborah // U.S. News & World Report;10/29/2007, Vol. 143 Issue 15, p53 

    The article discusses the debate over inoculating young girls with the human papillomavirus (HPV) vaccine. The vaccine protects against four types of HPV, two of which cause genital warts and two of which are responsible for up to 70 percent of cervical cancers. The concern over giving the...

  • Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. Harper, Diane M.; Irons, Billy B.; Alexander, Natalie M.; Comes, Johanna C.; Smith, Melissa S.; Heutinck, Melinda A.; Handley, Sandra M.; Ahern, Debra A. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Objective: Only a portion of the US population is willing to consider HPV vaccination to date. The primary aim of this study is to determine the decisional satisfaction associated with HPV vaccination. Study Design: This is a prospective survey conducted at an urban college where women...

  • Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. Hillemanns, Peter; Petry, Karl; Largeron, Nathalie; McAllister, Ruth; Tolley, Keith; B├╝sch, Katharina // Journal of Public Health (09431853);Apr2009, Vol. 17 Issue 2, p77 

    Clinical trials have demonstrated the efficacy of the tetravalent human papillomavirus (HPV) vaccination in the prevention of cervical cancer and genital warts associated with HPV types 6, 11, 16 and 18. We used an empirically calibrated Markov cohort model of the natural history of HPV to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics